Sandra Ann Springer MD

Associate Professor of Medicine (AIDS) and Associate Clinical Professor of Nursing; Director, Infectious Disease Outpatient Clinic, Veterans Administration Healthcare Services, Newington


Sandra Springer, MD is an Associate Professor of Medicine in the Department of Internal Medicine, Section of Infectious Diseases at the Yale School of Medicine. She is also the Director of the Infectious Disease (ID) Clinic at the Newington site of t and an Attending ID physician at the West Haven site of the VA Connecticut Healthcare System (VACHS). She is board-Certified in Internal Medicine, Infectious Diseases and Addiction Medicine. She has significant clinical and research experience with persons with alcohol and substance use disorders and with persons living with HIV (PLH). She has completed a 5-year NIDA K02 Independent Scientist Award developing interventions to improve adherence to antiretroviral therapy (ART) among PLH with comorbid substance use disorders.She was also a former recipient of a NIDA-funded K23 Mentored Career Development Award where she evaluated the use of medication-assisted treatment (MAT) to prevent relapse to opioid use as a conduit to care among HIV-infected opioid dependent released prisoners. During this project she developed the first protocol to use buprenorphine to improve HIV treatment outcomes as relapse prevention for opioid dependent HIV+ prisoners. She has considerable research experience conducting randomized controlled trials (RCTs) with the use of extended-release naltrexone (XR-NTX) and has been a principal investigator (PI) on several R01s including one funded by the NIAAA to evaluate XR-NTX to improve HIV treatment outcomes via preventing relapse to alcohol use among HIV infected prisoners with alcohol use disorders (AUDs) transitioning to the community; PI on a NIDA R01 that evaluated XR-NTX to improve HIV treatment outcomes and prevent relapse to opioid use among opioid dependent released CJ-populations; and she was recently awarded an R01 from NIDA as co-PI with Dr. Al Shaw, also in the section of ID here at Yale, in 2016 evaluating immunobiological outcomes among persons with opioid use disorders starting MAT. In addition she has been co-Investigator on 2 R01s funded by NIDA (1) using Buprenorphine to improve HIV and opioid treatment outcomes among HIV+ persons with a history of CJS involvement in Washington, D.C.; and (2) to implement MAT with XR-NTX with opioid dependent persons in Ukraine. Thus she has considerable expertise with HIV and substance use disorders and conducting research.